Management of kawasaki disease in resource-limited settings

Pediatric Infectious Disease Journal

Volumn 34, Issue 1, 2015, Pages 94-96

  Singh, Surjit ^a   Newburger, Jane W ^b   Kuijpers, Taco ^c   Burgner, David ^d,e,f  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MONASH CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; ACETYLSALICYLIC ACID; IMMUNOLOGIC FACTOR;

AUSTRALIA; CORONARY ARTERY DISEASE; DENGUE; DIAGNOSTIC TEST; EUROPE; HEALTH CARE AVAILABILITY; HUMAN; INCIDENCE; INDIA; JAPANESE (PEOPLE); KOREA; MEASLES; MEDICAL SPECIALIST; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATIC FEVER; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOCYTOSIS; DEVELOPING COUNTRY;

ASPIRIN; DEVELOPING COUNTRIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84926008580     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000600     Document Type: Review

References (19)

1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533-544.
2. Yim D, Curtis N, Cheung M, et al. Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J Paediatr Child Health. 2013;49:704-708.
3. MacNeil A, Holman RC, Yorita KL, et al. Evaluation of seasonal patterns of Kawasaki syndromeand rotavirus-associated hospitalizations in California and New York, 2000-2005. BMC Pediatr. 2009;9:65.
4. Tacke CE, Breunis WB, Pereira RR, et al. Five years of Kawasaki disease in the Netherlands: a national surveillance study. Pediatr Infect Dis J. 2014;33:793-797.
5. Salo E. Epidemiology of Kawasaki disease in Northern Europe. Prog Clin Biol Res. 1987;250:67-70.
6. Kumar RK, Tandon R. Rheumatic fever & rheumatic heart disease: the last 50 years. Indian J Med Res 2013;137:643-658.
7. Singh S, Aulakh R, Bhalla AK, et al. Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child. 2011;96:137-140.
8. Huang SK, Lin MT, Chen HC, et al. Epidemiology of Kawasaki disease: prevalence from national database and future trends projection by system dynamics modeling. J Pediatr. 2013;163:126-131 e121.
9. Kushner HI, Macnee R, Burns JC. Impressions of Kawasaki syndrome in India. Indian Pediatr. 2006;43:939-942.
10. Yim D, Curtis N, Cheung M, et al. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health. 2013;49:614-623.
11. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733.
12. Lai CC, Lee PC, Wang CC, et al. Reaction at the bacillus Calmette-Guerin inoculation site in patients with Kawasaki disease. Pediatr Neonatol. 2013;54:43-48.
13. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888-893.
14. Ichihashi K, Shiraishi H, Momoi M. Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin-an effective and cost-saving schedule of therapy. Cardiol Young. 2009;19:224-227.
15. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158:831-835 e833.
16. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
17. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-675.
18. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-1620.
19. Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012;379:1571-1572.